News
Pipeline Digest Meets Specialty Drug Market Needs
EY Announces Dea Belazi of AscellaHealth as an Entrepreneur Of The Year 2023 National Finalist
PHL Inno - 5 Philadelphia-area companies make Deloitte's 2023 list of 500 fastest-growing tech firms
AscellaHealth Ranked Number 231 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
Would Proposed Changes on Interchangeability Diminish Designation?
Ensuring Timely, Secure Delivery of Therapies for Rare Diseases
AscellaHealth Earns Merit-Based Philadelphia100 Award for Fourth Consecutive Year, Ranks #10 Among Fastest Growing, Private Companies in Philadelphia Region
AscellaHealth Assesses New, Anticipated Specialty Treatments
AscellaHealth President and CEO Dea Belazi Delivers Impactful Discussion at 2023 SIIA Annual Meeting: Specialty Pharmaceuticals and their Impact on Self-Insured Employers
AscellaHealth Named 2023 Best Global Specialty Pharmacy & Healthcare Services Organisation
AscellaHealth Earns Number One Spot for Fastest Growing Private Company and Number Two Spot on Philadelphia Business Journal “Soaring 76” Overall List of Fastest-Growing Companies
AscellaHealth Launches Q3 2023 Specialty & Rare Pipeline Digest™: Expert Resource for FDA Approval Status of Specialty Pharmaceuticals and Cell & Gene Therapies
FDA Broadens Lonsurf Use in Colorectal Cancer
Now That Humira Biosimilars Have Launched, What Are Lessons Learned for Stelara Biosimilars?
Newer Drugs for ALL Are Hitting the U.S. Market, Potentially Filling Unmet Need
For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73 Percent
AscellaHealth: Providing a Rare and Special Perspective
AscellaHealth Releases Inaugural Specialty & Rare Pipeline Digest™: Includes FDA Approval Status for Specialty Drug Product Launches and Cell & Gene Therapies
NeuroSolv Therapeutics LLC Advances Spinal Cord Injury Treatment with Development of Perineline™ and Support from AscellaHealth LLC, a Global Healthcare & Specialty Pharmacy Solutions Company
Announcing the recipients of the 2023 Philadelphia Titan 100–Bill Oldham
Announcing the recipients of the 2023 Philadelphia Titan 100
Ahead of Influx of Humira Biosimilars, One Manufacturer Reveals ‘Aggressive’ Pricing Strategy
AscellaHealth Recognized Among Philadelphia Business Journal’s 2023 Best Places to Work
EY Announces Dea Belazi, CEO and President, AscellaHealth, as an Entrepreneur Of The Year 2023 Greater Philadelphia Award Winner
Slew of Adalimumab Biosimilars Are Expected in July
Coherus Reveals New Pricing Strategy for Its Humira Biosimilar
From international expansion to IPOs, this year's PACT Enterprise Award winners have big plans
AscellaHealth Recognized at 2023 PACT Enterprise Awards
Patients Often Lose in the Battle between Pharma and PBMs
AscellaHealth Captures Two Stevie Awards, Recognized as Fastest Growing Company and Marketing Department of the Year by 2023 American Business Awards
AscellaHealth Expands Worldwide Market Position, Unifies Solutions Under One Global Brand, Brings A Rare and Special Perspective to the Industry
Factors for Ensuring a Successful Launch and Market Access for Specialty Drugs and Novel Cell or Gene Therapies
EY Announces Dea Belazi, CEO and President, AscellaHealth, Entrepreneur Of The Year 2023 Greater Philadelphia Award Finalist
Critical Success Factors for Commercializing Specialty Drugs, Cell and Gene Therapies
Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs
AscellaHealth Recognized for Two Consecutive Years as One of “Americas' Fastest Growing Companies” by The Financial Times
AscellaHealth is 1 of 26 Philadelphia-area firms on Inc.’s List of Fastest-Growing Northeast Companies
AscellaHealth Ranks No. 48 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies
AscellaHealth Launches Biopharmaceutical Educational Podcast Series
Specialty Drug Tiering, Indication Expansions, IRA Are Some Issues to Watch
Humira Is Not Only Specialty Drug With Anticipated Biosimilars
Expect Rare Disease, Cancer, Immunology Drugs to Have Big Impact
More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends
FDA Approved Four New Gene Therapies, Other Novel Agents in 2022
2022 Saw Continued Approvals, Uptake of Biosimilars
Specialty Pharmacy Trends to Watch in 2023
Seven Specialty Pharmacy Trends to Watch in 2023
Potential of Gene and Cell Therapies for Patients with Rare/Orphan Diseases, Ensuring Access to Treatment
PARP Inhibitors’ Data on Later Line Use in Ovarian Cancer Prompts Indication Withdrawals
AscellaHealth is One of Four Philadelphia-area companies which rank among Deloitte's 500 fastest-growing tech firms
AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
AscellaHealth - A Global Partner in Specialty Pharmacy Services for Life Sciences
Meeting the needs of rare disease patients: Improved access to specialty pharmaceuticals, gene and cell therapies
AscellaHealth Earns Merit-Based Philadelphia100 Award for Third Consecutive Year, Ranks Among Fastest Growing, Private Companies in Philadelphia Region
AscellaHealth Earns Spot on Philadelphia Business Journal “Soaring 76” List of Fastest-Growing Companies
AscellaHealth Named National Association of Specialty Pharmacy [NASP] Strategic Channel Partner of the Year
Survey Finds That Payers Are Covering Sequential Use of SMA Agents
AscellaHealth and Optime Care Collaborate with National Association of Specialty Pharmacy, Releases Podcast Series on Rare Disease Patient Journey
Deploying Next-Generation Technologies to Optimize Patient Care
AscellaHealth Family of Companies is Founding Sponsor of Inaugural Gene Therapy and Specialty Pharmacy Awareness Month, September 2022
AscellaHealth Named Philadelphia Business Journal PHL Inno 2022 Fire Award Honoree
AscellaHealth Achieves Favorable Ranking Among Prestigious 2022 Inc. Magazine’s 5000 Honorees: The Most Successful Companies in America For Second Consecutive Year
Terebellum, Global Healthcare and Specialty Pharmacy Solutions Company, Hosts Strategic Sessions to Architect 2023 International Pharmaceutical Partnerships and Management Training Programs
AscellaHealth and Dea Belazi honored in 2022 Fire Awards
Potential Expansion of Treatment Options for Breast Cancer
U.S. Sees First Ophthalmologic Biosimilar Launch in Crowded, High-Cost Space
Dea Belazi Named 2022 Titan 100 Award, Recognizing Philadelphia’s Top 100 CEO’s & C-level Executives
Cushing’s Syndrome
AscellaHealth Family of Companies Expands Subsidiary Terebellum’s Operations into Germany and United Kingdom, Adds New Executive Positions
Carvykti Approval Brings Second CAR-T to Multiple Myeloma Treatment
Ernst & Young Names Dea Belazi, CEO and President, AscellaHealth, Entrepreneur Of The Year 2022 Greater Philadelphia Award Finalist
AscellaHealth Awarded as One of The Financial Times’ “Americas' Fastest Growing Companies 2022” For Contribution to North and South America’s Economic Growth
AscellaHealth: Stalwarts of Specialty Pharmacy
AscellaHealth Earns Stevie Award, Named Gold Winner as Small Company of the Year for Pharmaceuticals by 2022 American Business Awards
The AscellaHealth Family of Companies Expands Executive Team Leadership for Ongoing Support of Strategic Business Initiatives and Accelerated Growth
AscellaHealth Launches Family of Companies, Expands Specialty Pharmacy Services and Capabilities to Serve Patients, Payers, Pharmaceutical Manufacturers and Providers
Success with SP Solutions
AscellaHealth’s Hub Solutions for Life Sciences Ensures Specialty Product Access and Market Entry, Optimizes Outcomes for Rare Disease Patients
Ask an Adviser: How can we cut specialty pharmacy costs?
Innovative Patient-First Approach Enhances Patient Journey, Mitigates Rising Costs for Rare Disease Drugs
AscellaHealth Hosts Specialty Pharmacy Carve-Out Webinar, Supports Self-Insured Employers and Plan Sponsors with Strategies to Manage Specialty Medical Benefit Rx Costs
With New Data, Oncopeptides Rescinds Pepaxto Withdrawal
Drug Pricing Remains Hot Topic, but Legislation Addressing It Has Stalled
Biosimilar Approvals Are Expected to Undergo Upward Trend in 2022
2022 Outlook: Notable FDA Approvals, Payer Strategies Are Specialty Trends
Optime Care Collaborates with National Association of Specialty Pharmacy, Develops Podcast on Patient Journey Across Specialty Pharmacy & Healthcare
AscellaHealth Enhances Site of Care Optimization, Awards Leading Pharmacies, Including Walmart, Preferred Status for Home Infusion Pharmacy Network
CMS Proposed NCD Will Provide Limited Medicare Coverage of Aduhelm, Other Similar Therapies
AscellaHealth Designates Preferred Status to Leading Pharmacies for Home Infusion Pharmacy Network, Enhances Site of Care Optimization
Specialty Pharmacy, Home Infusion Spaces Saw Myriad 2021 Changes
Notable 2021 Approvals Included Oncolytics, Interchangeables
Medicare Plans to Cover Aduhelm but With Certain Restrictions
AscellaHealth Awards Walmart Preferred Status for Home Infusion Pharmacy Network
Looking Forward to 2022, COVID-19 Will Continue to Impact Pharma in Myriad Ways
Innovative New Drugs, Collaborative Efforts, Digital Health Care Deals Were Among 2021 Trends
AscellaHealth Launches Expanded Website: User-Friendly Content on Global Specialty Pharmacy and Healthcare Services for Patients, Payers, Life Sciences and Providers
AscellaHealth Ranked Number 299 Fastest Growing Company in North America on the 2021 Deloitte Technology Fast 500™
AscellaHealth Forges Strategic Alliance with Optime Care
Dea Belazi’s blog on how technology advancements impact patient care
Daratumumab-RVd Demonstrates Clinical Benefits For Certain Patients With Multiple Myeloma